July 13, 2022Open Access

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

Key Points

Key points are not available for this paper at this time.

Abstract

Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.).

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper

Cite This Study

Ansell et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8240805ee2ba81dbef266 https://doi.org/https://doi.org/10.1056/nejmoa2206125

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial2021 · 160 citations
2Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials2020 · 48 citations
3PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study2019 · 210 citations
4Combination of the anti‐CD30‐auristatin‐E antibody‐drug conjugate (SGN‐35) with chemotherapy improves antitumour activity in Hodgkin lymphoma2008 · 118 citations
5Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network2014 · 73 citations

KI fragen

Bookmark

View Full Paper